Syncom Formulations (India) DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023


0.76×	0.76×	0.75×	0.75×	0.76×
1.39×	1.43×	1.34×	1.36×	1.76×
16.3%	14.5%	10.5%	9.5%	6.7%
1.03×	1.03×	1.14×	0.67×	0.59×
1.29×	1.29×	1.21×	1.40×	1.48×
22.8%	20.7%	14.6%	9.0%	7.8%
20.2%	20.2%	15.7%	9.3%	7.8%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

SYNCOMF₹21.20

Syncom Formulations (India) Limited

· Pharma & Health

₹ CrorePeersHESTERBIO NGLFINE WINDLAS JAGSNPHARMAMRUTANJAN INDOCO SAIPARENTMcap ₹1,993 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.76	0.75	0.75	0.76	0.76
Interest Burden (Pretax/EBIT) ×	1.76	1.36	1.34	1.43	1.39
EBIT Margin %	6.73	9.46	10.52	14.49	16.29
Asset Turnover ×	0.59	0.67	1.14	1.03	1.03
Financial Leverage (Assets/Equity) ×	1.48	1.40	1.21	1.29	1.29
ROE (5-step product, year-end total equity) %	7.79	9.04	14.64	20.70	22.77
ROE (owners' profit / average owners' equity) %	7.84	9.30	15.69	20.19	20.19

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.